JP2017514801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514801A5
JP2017514801A5 JP2016561311A JP2016561311A JP2017514801A5 JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5 JP 2016561311 A JP2016561311 A JP 2016561311A JP 2016561311 A JP2016561311 A JP 2016561311A JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5
Authority
JP
Japan
Prior art keywords
xaa
chem
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514801A (ja
JP6768515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057442 external-priority patent/WO2015155151A1/en
Publication of JP2017514801A publication Critical patent/JP2017514801A/ja
Publication of JP2017514801A5 publication Critical patent/JP2017514801A5/ja
Application granted granted Critical
Publication of JP6768515B2 publication Critical patent/JP6768515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561311A 2014-04-07 2015-04-07 二重アシル化glp−1化合物 Active JP6768515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163697 2014-04-07
EP14163697.7 2014-04-07
PCT/EP2015/057442 WO2015155151A1 (en) 2014-04-07 2015-04-07 Double-acylated glp-1 compounds

Publications (3)

Publication Number Publication Date
JP2017514801A JP2017514801A (ja) 2017-06-08
JP2017514801A5 true JP2017514801A5 (OSRAM) 2018-05-10
JP6768515B2 JP6768515B2 (ja) 2020-10-14

Family

ID=50434120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561311A Active JP6768515B2 (ja) 2014-04-07 2015-04-07 二重アシル化glp−1化合物

Country Status (6)

Country Link
US (1) US10689429B2 (OSRAM)
EP (1) EP3129041B1 (OSRAM)
JP (1) JP6768515B2 (OSRAM)
CN (1) CN106132985B (OSRAM)
ES (1) ES2741507T3 (OSRAM)
WO (1) WO2015155151A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー/エス Glp−1組成物及びその使用
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113195524A (zh) 2018-10-11 2021-07-30 因塔西亚治疗公司 人类胰淀素类似物多肽和使用方法
CN111378027B (zh) * 2018-12-29 2022-04-15 万新医药科技(苏州)有限公司 一种索玛鲁肽前体的制备方法
WO2021043803A1 (en) * 2019-09-02 2021-03-11 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
KR20220110731A (ko) 2019-11-06 2022-08-09 노보 노르디스크 에이/에스 치매에서의 glp-1 수용체 작용제
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
US20230165939A1 (en) 2020-04-29 2023-06-01 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如glp—1之肽治療劑的口服投與
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
AU2610699A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Glp-1 유도체 및 그의 경점막 흡수형 제제
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP2013514322A (ja) * 2009-12-16 2013-04-25 ノヴォ ノルディスク アー/エス 修飾されたn末端を有するglp−1受容体アゴニスト化合物
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
WO2012098188A1 (en) * 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 particles and compositions
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
CN104039822A (zh) * 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
AU2014210751A1 (en) * 2013-01-29 2015-08-06 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2017514801A5 (OSRAM)
JP2014529629A5 (OSRAM)
JP2013543853A5 (OSRAM)
JP2014501712A5 (OSRAM)
JP2015517478A5 (OSRAM)
JP2015517477A5 (OSRAM)
JP2010538049A5 (OSRAM)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
TWI362392B (en) Acylated glp-1 compounds
JP2016529253A5 (OSRAM)
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP5755398B2 (ja) 伸長されたglp−1化合物
JP2008533105A5 (OSRAM)
CN104519902B (zh) 双酰化glp‑1衍生物
JP2018505146A5 (OSRAM)
JP2012529463A5 (OSRAM)
JP2023510219A (ja) インスリン誘導体
JP2010529004A5 (OSRAM)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2012506402A5 (OSRAM)
JP2005528337A5 (OSRAM)
JP2024059696A (ja) 5.8~8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液
NZ597554A (en) Selective glucagon-like-peptide-2 (glp-2) analogues
WO2015013169A3 (en) Bioconjugates of synthetic apelin polypeptides
JP2017528419A5 (OSRAM)